[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Antiviral game changer", "description": "Is this antiviral a game changer, Oral Antiviral, molnupiravir \n\nhttps://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/\n\nMerck and Ridgeback\n\nOral Antiviral, molnupiravir (MK-4482, EIDD-2801)\n\nPositive Interim Analysis of Phase 3 Study\n\nSignificantly reduced the risk of hospitalization or death\n\nDuring day 1 to 5 to 29 days\n\nPhase 3 MOVe-OUT trial \n\nAt risk, non-hospitalized adults with mild-to-moderate COVID-19 \n\nA global Phase 3, randomized, placebo-controlled, double-blind, multi-site study \n\nof non-hospitalized adult patients\n\nBrazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan, Mexico, Philippines, Poland, Russia, South Africa, Spain, Sweden, Taiwan, Ukraine, the United Kingdom and the United States\n\nEligibility criteria\n\nLaboratory-confirmed mild-to-moderate COVID-19\n\nWith symptom onset within 5 days of study randomization\n\nAll patients were required to have at least one risk factor\n\nMolnupiravir group\n\nHospitalization or dead, 7.3% of patients\n28 out of 385\n\nNo deaths\n\nPlacebo group\n\nHospitalization or dead, 14.1% of patients\n53 out of 377\n\nP is 0.0012\n\n8 deaths\n\nData Monitoring Committee in consultation with Food and Drug Administration\n\nRecruitment into the study stopped early \n\nDue to these positive results\n\nMerck, application for Emergency Use \n\nAuthorization in US\n\nOther regulatory bodies worldwide\n\nAbout the Results of the Planned Interim Analysis\n\nEvaluated data n = 775\n\nRecruitment 90% of 1,550 the intended sample \n\nMolnupiravir reduced the risk of hospitalization and/or death across all key subgroups; \n\nEfficacy was not affected by timing of symptom onset or underlying risk factor\n\nAbout 40% of participants had sequencing data\n\nMolnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu\n\nIncidence of adverse event between groups\n\nMolnupiravir group\n\nIncidence of any adverse event, 35%\n\nDrug-related adverse events, 12%\n\nSubjects discontinued study therapy due to an adverse event, 1.3%\n\nPlacebo groups\n\nIncidence of any adverse event, 40%\n\nDrug-related adverse events, 11%\n\nSubjects discontinued study therapy due to an adverse event, 3.4%\n\nMerck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, \n\nbut men enrolled in its trials had to abstain from intercourse or agree to use contraception. \n\nWomen of child-bearing age in the study could (not) be pregnant and also had to use birth control.\n\nhttps://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01/\n\nAbout Merck\u2019s Efforts to Enable Access to Molnupiravir, if it is Granted EUA or Approval\n\nMerck has been producing molnupiravir at risk. \n\nMerck expects to produce 10 million courses of treatment by the end of 2021\n\nExisting procurement agreement with the U.S. Government\n\nMerck will supply approximately 1.7 million courses of molnupiravir to the U.S. government upon EAU\n\n$700 per 5 day course (2 doses per day)\n\n$1.2 billion purchase agreement for the \n\n1.7 million 5-day treatment courses of molnupiravir \n\n\nMOVe-AHEAD\nA global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study, \n\nevaluating the efficacy and safety of molnupiravir in preventing the spread of COVID-19 within households", "link": "https://www.youtube.com/watch?v=qVW2QqHUJUw", "date_published": "2021-10-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]